5 Reasons This Growth Stock Is Up 23% So Far in 2019
Danaher's management continues to transform the conglomerate, and the GE Biopharma deal looks like an even better value after a recent disclosure.
https://fxn.ws/2XRvcEa
Subscribe to:
Post Comments
(
Atom
)
Post a Comment